A multicentre single arm study to evaluate the safety and efficacy of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (TE NDMM) patients refractory to initial bortezomib-based induction therapy

DOI number 10.58109/fpth-dx17
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Andrew Spencer (Alfred Hospital)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 50 patients with newly diagnosed, transplant eligible, multiple myeloma using carfilzomib-thalidomide-dexamethasone (CarTD), in a randomised trial
  • Demographic data
  • Diagnostic, data
  • Treatment data
  • Outcome data
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Chemotherapy
ANZCTR Reference ACTRN12615000934549
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
MM06
MM20